Evanthia Galanis Selected Research

src-Family Kinases

11/2019	A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
1/2013	Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Evanthia Galanis Research Topics

Disease

86	Neoplasms (Cancer) 01/2024 - 02/2002
43	Glioblastoma (Glioblastoma Multiforme) 01/2024 - 04/2005
23	Glioma (Gliomas) 01/2024 - 11/2004
16	Infections 12/2023 - 11/2003
13	Breast Neoplasms (Breast Cancer) 01/2021 - 09/2006
10	Ovarian Neoplasms (Ovarian Cancer) 02/2023 - 08/2002
10	Measles 01/2021 - 08/2002
9	Neoplasm Metastasis (Metastasis) 12/2022 - 09/2009
8	Brain Neoplasms (Brain Tumor) 12/2022 - 02/2011
4	Disease Progression 07/2023 - 04/2008
4	Astrocytoma (Pilocytic Astrocytoma) 01/2023 - 08/2014
4	Oligodendroglioma 01/2022 - 07/2019
4	Hematologic Neoplasms (Hematological Malignancy) 10/2018 - 08/2002
4	Melanoma (Melanoma, Malignant) 01/2017 - 02/2002
3	Triple Negative Breast Neoplasms 01/2021 - 09/2014
3	Multiple Myeloma 01/2018 - 07/2009
3	Fatigue 01/2018 - 07/2009
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2017 - 07/2009
3	Sarcoma (Soft Tissue Sarcoma) 01/2016 - 06/2002
3	Prostatic Neoplasms (Prostate Cancer) 12/2009 - 01/2009
2	Craniopharyngioma (Craniopharyngiomas) 07/2023 - 04/2018
2	Hyperglycemia 07/2023 - 01/2018
2	Meningioma (Meningiomas) 01/2023 - 01/2019
2	Medulloblastoma 01/2022 - 11/2012
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2018 - 02/2002
2	Communicable Diseases (Infectious Diseases) 01/2016 - 10/2013
2	Chromosomal Instability (Chromosome Stability) 01/2015 - 09/2014
2	Inflammation (Inflammations) 10/2012 - 02/2011
2	Virus Diseases (Viral Diseases) 10/2012 - 10/2012
2	Pleural Effusion (Pleural Effusions) 06/2012 - 08/2010

Drug/Important Bio-Agent (IBA)

18	VaccinesIBA 01/2024 - 08/2002
12	Proteins (Proteins, Gene)FDA Link 09/2022 - 12/2006
10	Temozolomide (Temodar)FDA LinkGeneric 11/2023 - 10/2011
8	Bevacizumab (Avastin)FDA Link 01/2022 - 09/2009
7	Carcinoembryonic AntigenIBA 01/2024 - 09/2006
6	Aurora Kinase AIBA 01/2021 - 05/2013
5	Biomarkers (Surrogate Marker)IBA 09/2023 - 02/2011
5	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2023 - 01/2016
5	sodium-iodide symporter (sodium iodide symporter)IBA 01/2018 - 12/2009
5	ErbB Receptors (EGF Receptor)IBA 12/2016 - 04/2005
4	AntigensIBA 01/2022 - 10/2012
4	Vorinostat FDA Link 01/2018 - 04/2009
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016 - 04/2005
4	Phosphotransferases (Kinase)IBA 09/2014 - 08/2005
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2014 - 09/2009
4	Antineoplastic Agents (Antineoplastics)IBA 09/2009 - 08/2002
3	Antiviral Agents (Antivirals)IBA 12/2023 - 12/2009
3	RNA (Ribonucleic Acid)IBA 10/2018 - 10/2012
3	TOR Serine-Threonine KinasesIBA 01/2018 - 08/2005
3	LigandsIBA 01/2017 - 11/2004
3	Peptides (Polypeptides)IBA 01/2017 - 08/2002
3	Anticonvulsants (Antiepileptic Drugs)IBA 11/2015 - 10/2005
3	EnzymesIBA 11/2015 - 10/2005
3	Irinotecan (Camptosar)FDA LinkGeneric 11/2015 - 10/2003
3	Everolimus FDA Link 09/2015 - 06/2008
3	Interleukin-13IBA 04/2012 - 09/2008
3	Histone Deacetylase InhibitorsIBA 02/2012 - 04/2009
3	Green Fluorescent ProteinsIBA 10/2010 - 12/2006
3	epidermal growth factor receptor VIIIIBA 04/2007 - 12/2006
2	InterferonsIBA 12/2023 - 10/2018
2	Angiogenesis InhibitorsIBA 11/2023 - 04/2010
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2023 - 06/2008
2	MethyltransferasesIBA 09/2023 - 01/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2023 - 06/2012
2	FANG vaccineIBA 02/2023 - 01/2021
2	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2023 - 01/2019
2	src-Family KinasesIBA 11/2019 - 01/2013
2	Dasatinib (BMS 354825)FDA Link 11/2019 - 01/2013
2	Imatinib Mesylate (Gleevec)FDA Link 07/2019 - 07/2019
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 09/2009
2	temsirolimus FDA Link 01/2018 - 08/2005
2	Phenobarbital (Luminal)FDA Link 01/2018 - 09/2014
2	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 09/2013
2	Estrogen Receptor alphaIBA 01/2018 - 01/2014
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2017 - 01/2017
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2015 - 02/2010
2	PlatinumIBA 01/2015 - 02/2010
2	Hormones (Hormone)IBA 01/2014 - 06/2012
2	AntibodiesIBA 03/2013 - 12/2009
2	Complement System Proteins (Complement)IBA 03/2013 - 07/2008
2	Immunoglobulin G (IgG)IBA 03/2013 - 08/2009
2	Virulence Factors (Pathogenicity Factors)IBA 10/2012 - 02/2011
2	Platinum Compounds (Compounds, Platinum)IBA 10/2012 - 10/2005
2	CytokinesIBA 06/2012 - 02/2011
2	Interleukin-13 Receptors (Interleukin 13 Receptor)IBA 04/2012 - 09/2008
2	Neutralizing AntibodiesIBA 02/2011 - 04/2003
2	Immunoglobulins (Immunoglobulin)IBA 08/2009 - 07/2008
2	dl1520 (ONYX-015)IBA 01/2009 - 04/2003
2	Gemcitabine FDA Link 05/2008 - 06/2002
2	DNA (Deoxyribonucleic Acid)IBA 12/2004 - 04/2003
1	cobimetinibIBA 07/2023

Therapy/Procedure

48	Therapeutics 12/2023 - 08/2002
20	Radiotherapy 11/2023 - 12/2007
17	Drug Therapy (Chemotherapy) 01/2021 - 06/2002
13	Immunotherapy 02/2023 - 02/2002
4	Oncolytic Virotherapy 01/2019 - 01/2009
3	Intravenous Administration 10/2012 - 11/2003
2	Chemoradiotherapy 11/2023 - 04/2010
2	Injections 01/2009 - 04/2005
1	Conformal Radiotherapy 11/2023